公司資料
AC Immune 股價、新聞與催化劑
- 股票代碼:
- ACIU
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Switzerland and listed in the U
股票表現
2.53 USD (+1.61%)
收盤價
最後更新: 2026年8月17日
246M USD
市值
股價為何變動
As of Aug 17, 2026, ACIU closed up 1.61% at $2.53. No new same-company headline was identified in the current news window.
公司概覽
Precision Neurodegeneration
AC Immune develops therapeutics and diagnostics for neurodegenerative diseases driven by protein misfolding and inflammation. Its portfolio combines active immunotherapies, small molecules and PET imaging agents.
ACI-7104
ACI-7104 is an active immunotherapy targeting alpha-synuclein in early Parkinson’s disease. Interim Phase 2 VacSYn results showed strong immunogenicity and suggested a potential slowing of clinical progression.
Alzheimer’s Immunotherapies
ACI-24 is an anti-amyloid active immunotherapy in the Phase 2 ABATE trial, while ACI-35 targets pathological tau. Both programs form part of AC Immune’s partnered clinical-stage vaccine portfolio.
Morphomer Small Molecules
The Morphomer platform creates brain-penetrant small molecules targeting intracellular protein pathology. Programs include tau aggregation inhibitors and ACI-19764, an NLRP3 inflammasome inhibitor now in Phase 1 testing.
Diagnostic Tracers
AC Immune also develops PET tracers for neurodegenerative pathology, including TDP-43. These tools could improve patient selection and disease monitoring in conditions that currently lack specific imaging biomarkers.
未來催化劑
- Interim Phase 2 ABATE results from the ACI-24 AD3 cohort expected in the first half of 2026.
- Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
- IND-enabling studies for the Morphomer-Tau program expected to begin in the first half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。